Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON TM-5 BI 764532 dose-selection study in relapsed/refractory extensive-stage small cell lung cancer and other neuroendocrine carcinomas
CTR20232621Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of obrixtamig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), large cell neuroendocrine carcinoma (LCNEC), sponsored by Boehringer Ingelheim. Started Oct 2023; status: active.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on CTR20232621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232621.